Oncotarget

Reviews:

Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers

Mary Glorieux, Rüveyda Dok and Sandra Nuyts _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:81662-81678. https://doi.org/10.18632/oncotarget.20953

Metrics: PDF 1189 views  |   HTML 2217 views  |   ?  


Abstract

Mary Glorieux1, Rüveyda Dok1 and Sandra Nuyts1,2

1KU Leuven, University of Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, 3000 Leuven, Belgium

2Department of Radiation Oncology, Leuven Cancer Institute, UZ Leuven, 3000 Leuven, Belgium

Correspondence to:

Sandra Nuyts, email: sandra.nuyts@uzleuven.be

Keywords: HNSCC, DNA targeted agents, radiation sensitization, biomarkers

Received: June 13, 2017     Accepted: August 27, 2017     Published: September 16, 2017

ABSTRACT

Head and neck squamous cell carcinoma is the sixth most common cancer worldwide and despite advances in treatment over the last years, there is still a relapse rate of 50%. New therapeutic agents are awaited to increase the survival of patients. DNA repair targeted agents in combination with standard DNA damaging therapies are a recent evolution in cancer treatment. These agents focus on the DNA damage repair pathways in cancer cells, which are often involved in therapeutic resistance. Interesting targets to overcome these cancer defense mechanisms are: PARP, DNA-PK, PI3K, ATM, ATR, CHK1/2, and WEE1 inhibitors. The application of DNA targeted agents in head and neck squamous cell cancer showed promising preclinical results which are translated to multiple ongoing clinical trials, although no FDA approval has emerged yet. Biomarkers are necessary to select the patients that can benefit the most from this treatment, although adequate biomarkers are limited and validation is needed to predict therapeutic response.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20953